Modern subunit vaccines: development, components, and research opportunities PM Moyle, I Toth ChemMedChem 8 (3), 360-376, 2013 | 480 | 2013 |
Self-adjuvanting lipopeptide vaccines PM Moyle, I Toth Current medicinal chemistry 15 (5), 506-516, 2008 | 186 | 2008 |
Mucosal immunisation: adjuvants and delivery systems PM Moyle, RP McGeary, JT Blanchfield, I Toth Current Drug Delivery 1 (4), 385-396, 2004 | 102 | 2004 |
Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines PM Moyle Biotechnology advances 35 (3), 375-389, 2017 | 97 | 2017 |
Glucagon‐like peptide‐1 (GLP‐1)‐based therapeutics: current status and future opportunities beyond type 2 diabetes JY Cheang, PM Moyle ChemMedChem 13 (7), 662-671, 2018 | 87 | 2018 |
Soil bacterial diffusible and volatile organic compounds inhibit Phytophthora capsici and promote plant growth SF Syed-Ab-Rahman, LC Carvalhais, ET Chua, FY Chung, PM Moyle, ... Science of the Total Environment 692, 267-280, 2019 | 80 | 2019 |
Method for the synthesis of mono-ADP-ribose conjugated peptides PM Moyle, TW Muir Journal of the American Chemical Society 132 (45), 15878-15880, 2010 | 71 | 2010 |
Structure–activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates ABM Abdel-Aal, MR Batzloff, Y Fujita, N Barozzi, A Faria, P Simerska, ... Journal of medicinal chemistry 51 (1), 167-172, 2008 | 70 | 2008 |
Glucagon-like peptide-1 receptor agonists and strategies to improve their efficiency SE Alavi, PJ Cabot, PM Moyle Molecular Pharmaceutics 16 (6), 2278-2295, 2019 | 65 | 2019 |
Modern lipid‐, carbohydrate‐, and peptide‐based delivery systems for peptide, vaccine, and gene products P Simerska, PM Moyle, I Toth Medicinal research reviews 31 (4), 520-547, 2011 | 64 | 2011 |
An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model T Rivera-Hernandez, DG Carnathan, S Jones, AJ Cork, MR Davies, ... MBio 10 (2), 10.1128/mbio. 00693-19, 2019 | 62* | 2019 |
Polymer–peptide hybrids as a highly immunogenic single-dose nanovaccine AAH Ahmad Fuaad, Z Jia, M Zaman, J Hartas, ZM Ziora, IC Lin, PM Moyle, ... Nanomedicine 9 (1), 35-43, 2014 | 57 | 2014 |
Differing efficacies of lead group A streptococcal vaccine candidates and full-length M protein in cutaneous and invasive disease models T Rivera-Hernandez, M Pandey, A Henningham, J Cole, B Choudhury, ... MBio 7 (3), 10.1128/mbio. 00618-16, 2016 | 56 | 2016 |
Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines PM Moyle, W Dai, Y Zhang, MR Batzloff, MF Good, I Toth Bioconjugate chemistry 25 (5), 965-978, 2014 | 55 | 2014 |
Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines PM Moyle, C Olive, MF Ho, M Pandey, J Dyer, A Suhrbier, Y Fujita, I Toth Journal of medicinal chemistry 50 (19), 4721-4727, 2007 | 52 | 2007 |
Bioconjugation approaches to producing subunit vaccines composed of protein or peptide antigens and covalently attached toll-like receptor ligands Z Xu, PM Moyle Bioconjugate chemistry 29 (3), 572-586, 2017 | 51 | 2017 |
Oral vaccine delivery-new strategies and technologies P Simerska, PM Moyle, C Olive, I Toth Current Drug Delivery 6 (4), 347-358, 2009 | 50 | 2009 |
Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity M Zaman, S Chandrudu, AK Giddam, J Reiman, M Skwarczynski, ... Nanomedicine 9 (17), 2613-2624, 2014 | 48 | 2014 |
The contribution of non-human primate models to the development of human vaccines T Rivera-Hernandez, DG Carnathan, PM Moyle, I Toth, NP West, ... Discovery medicine 18 (101), 313, 2014 | 45 | 2014 |
Sortase A (SrtA) inhibitors as an alternative treatment for superbug infections S Alharthi, SE Alavi, PM Moyle, ZM Ziora Drug Discovery Today 26 (9), 2164-2172, 2021 | 44 | 2021 |